GAM
HRTX icon

Gotham Asset Management’s Heron Therapeutics HRTX Stock Holding History

Gotham Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,220
Closed -$42.8K – 1466
2024
Q2 		$42.8K Buy
+12,220
New +$37.5K ﹤0.01% 1398
2022
Q4 		– Sell
-12,713
Closed -$54K – 1256
2022
Q3 		$54K Buy
+12,713
New +$49.7K ﹤0.01% 1150
2020
Q1 		– Sell
-10,837
Closed -$255K – 1132
2019
Q4 		$255K Buy
+10,837
New +$240K ﹤0.01% 983

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gotham Asset Management's HRTX Position: Q3 2024 in Review

Gotham Asset Management sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 12,220 shares — an estimated $42.8K sold.

Gotham Asset Management first reported a position in HRTX in Q4 2019 and held it in 3 quarters. The position peaked at $255K in Q4 2019. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Gotham Asset Management reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Gotham Asset Management sold 12,220 Heron Therapeutics shares in Q3 2024, an estimated $42.8K.
  • Gotham Asset Management first reported a position in Heron Therapeutics in Q4 2019 and held it in 3 quarters.
  • Gotham Asset Management's Heron Therapeutics position peaked at $255K in Q4 2019.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Gotham Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.